|Healthcare Review: MannKind Corporation, StemCells Inc, Pluristem Therapeutics Inc, Rosetta Genomics Ltd, Infinity Pharmaceuticals|
|By Staff and Wire Reports|
|Tuesday, 04 June 2013 13:31|
Following are notable movers at mid day on Tuesday:-
MannKind Corporation (NASDAQ:MNKD) shares decreased 2.10% to $7.47. The company on May 31 announced that all follow-up visits have been completed for the patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler. MannKind expects to release data from this study later this summer.
StemCells Inc. (NASDAQ:STEM) shares increased 3.38% to $1.84.The company on June 3 announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial, currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a treatment for chronic spinal cord injury. With this authorization from Health Canada, the Company is actively working to open one or more trial sites in Canada and begin screening patients.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) stock plunged 14.97% to $2.84. Investment analysts at MLV Capital started coverage on shares of PSTI in a note issued to investors on June 3. The firm set a “buy” rating and a $4.50 price target on the stock. MLV Capital’s price target would indicate a potential upside of 43.31% from the company’s current price.
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) stock jumped 4.93% to $3.83. The company on May 20 announced that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred Provider Organization (PPO), for the inclusion of Rosetta Genomics' miRview® mets2 test in Prime Health's covered products and services.
The agreement with Prime Health is the first credentialing agreement executed between Rosetta Genomics and a U.S. PPO, and increases the number of covered lives for which its miRview® mets2 test could be adjudicated as "in-network" to more than 6.5 million.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares climbed 18.22% to $19.40. The company, on June 3, announced updated Phase 1 data at ASCO from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory chronic lymphocytic leukemia.
Additionally, the company will be presenting at the Jefferies 2013 Global Healthcare Conference on June 4, 2013, at 3:00 p.m. ET in New York.